REPL vs AMGN vs IMVT vs CGEN vs IOVA

For growth investors, Iovance Biotherapeutics, Inc.

(IOVA) is the stronger pick with 60. 6% revenue growth year-over-year, versus -16. 7% for Compugen Ltd. (CGEN). Amgen Inc. (AMGN) offers the better valuation at 23. 1x trailing P/E (14. 7x forward), making it the more compelling value choice. Analysts rate Replimune Group, Inc. (REPL) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +62. 4%, compared to -90. 7% for Replimune Group, Inc. (REPL). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus REPL's -78. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amgen Inc.

(AMGN) is the lower-risk stock at 0. 60β versus Iovance Biotherapeutics, Inc. 's 2. 01β — meaning IOVA is approximately 234% more volatile than AMGN relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Iovance Biotherapeutics, Inc.

(IOVA) is pulling ahead at 60. 6% versus -16. 7% for Compugen Ltd. (CGEN). On earnings-per-share growth, the picture is similar: Amgen Inc. grew EPS 88. 2% year-over-year, compared to -45. 2% for Immunovant, Inc.. Over a 3-year CAGR, CGEN leads at 66. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amgen Inc.

(AMGN) is the more profitable company, earning 21. 0% net margin versus -148. 4% for Iovance Biotherapeutics, Inc. — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMGN leads at 29. 1% versus -153. 1% for IOVA. At the gross margin level — before operating expenses — IOVA leads at 97. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for REPL: 274.

3% to $12. 50.

In this comparison, AMGN (2.

9% yield) pays a dividend. REPL, IMVT, CGEN, IOVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Amgen Inc.

(AMGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 60), 2. 9% yield, +156. 4% 10Y return). Iovance Biotherapeutics, Inc. (IOVA) carries a higher beta of 2. 01 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMGN: +156. 4%, IOVA: -34. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: REPL is a small-cap quality compounder stock; AMGN is a mid-cap quality compounder stock; IMVT is a small-cap quality compounder stock; CGEN is a small-cap quality compounder stock; IOVA is a small-cap high-growth stock. AMGN pays a dividend while REPL, IMVT, CGEN, IOVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.